Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 5/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7887988 | 0.95 | GNAO1 (0.54) | GNAO1KEAP1SMN1; SMN2ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL8901169 | 0.93 | GNAO1 (0.56) | GNAO1KEAP1SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL2238689 | 0.89 | GNAO1 (0.46) | GNAO1KEAP1SMN1; SMN2ALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL6407048 | 0.87 | GNAO1 (0.49) | GNAO1KEAP1SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL7128349 | 0.83 | GNAO1 (0.56) | GNAO1HRH3GNAI3GNAI1ITGB3 | |
| SCHEMBL5848080 | 0.83 | GNAO1 (0.56) | GNAO1HRH3GNAI3GNAI1ITGB3 | |
| SCHEMBL9824369 | 0.81 | GNAO1 (0.54) | GNAO1HRH3GNAI3GNAI1ITGB3 | |
| SCHEMBL7122133 | 0.81 | GNAO1 (0.54) | GNAO1HRH3GNAI3GNAI1ITGB3 | |
| SCHEMBL7895241 | 0.81 | ALDH1A1 (0.57) | KEAP1SMN1; SMN2ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL9675526 | 0.80 | NAAA (0.45) | KEAP1SMN1; SMN2ALDH1A1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277508-A1 | USE OF COMPOUND AS CYP2E1 INHIBITOR | Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) | 2023-09-07 | — | — | US | disclosed |
| EP-4205741-A1 | USE OF COMPOUND AS CYP2E1 INHIBITOR | Shanghai Ling Xi Biotechnology Development Co., Ltd. (CN) | 2023-07-05 | — | — | EP | disclosed |
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-1309587-A1 | CINNOLINE COMPOUNDS | AstraZeneca AB (SE) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | GNAO1 695/4885KEAP1 1613/4885SMN1; SMN2 1776/4885 |
| US-20230277508-A1 | USE OF COMPOUND AS CYP2E1 INHIBITOR | CYP2E1, CYP11B1, CYP27A1 | GNAO1 2080/4885KEAP1 179/4885SMN1; SMN2 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.